Abstract
The outcome for patients with diffuse large B-cell lymphomas improved dramatically in the last decade, and the opportunity for improving therapy for patients with peripheral T-cell lymphoma exists as we begin to study specific subtypes of the disease. It is entirely possible that patients with different genetic subtypes of diffuse large B-cell lymphoma will eventually require different treatments, and the same will be true for patients with subtypes of peripheral T-cell lymphoma. These possibilities will be the focus of clinical investigation over the next decade.
Original language | English (US) |
---|---|
Pages (from-to) | 179-182 |
Number of pages | 4 |
Journal | Transfusion and Apheresis Science |
Volume | 44 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2011 |
ASJC Scopus subject areas
- Hematology